The Beauty Health Company (NASDAQ: SKIN) reported Q4 EPS of $0.06, $0.02 better than the analyst estimate of $0.04. Revenue for the quarter came in at $98.1 million versus the consensus estimate of $94.73 million.

GUIDANCE:

The Beauty Health Company sees FY2023 EPS of $450.00-$470.00, versus the consensus of $439.60.

For earnings history and earnings-related data on The Beauty Health Company (SKIN) click here.